Literature DB >> 30355579

Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.

Carolina R Batista1,2,3, Michelle Lim1,2,3, Anne-Sophie Laramée1,2,3, Faisal Abu-Sardanah1,2,3, Li S Xu1,2,3, Rajon Hossain1,2,3, Gillian I Bell3,4, David A Hess3,4, Rodney P DeKoter1,2,3.   

Abstract

Precursor B-cell acute lymphoblastic leukemia (B-ALL) is associated with recurrent mutations that occur in cancer-initiating cells. There is a need to understand how driver mutations influence clonal evolution of leukemia. The E26-transformation-specific (ETS) transcription factors PU.1 and Spi-B (encoded by Spi1 and Spib) execute a critical role in B-cell development and serve as complementary tumor suppressors. Here, we used a mouse model to conditionally delete Spi1 and Spib genes in developing B cells. These mice developed B-ALL with a median time to euthanasia of 18 weeks. We performed RNA and whole-exome sequencing (WES) on leukemias isolated from Mb1-CreΔPB mice and identified single nucleotide variants (SNVs) in Jak1, Jak3, and Ikzf3 genes, resulting in amino acid sequence changes. Jak3 mutations resulted in amino acid substitutions located in the pseudo-kinase (R653H, V670A) and in the kinase (T844M) domains. Introduction of Jak3 T844M into Spi1/Spib-deficient precursor B cells was sufficient to promote proliferation in response to low IL-7 concentrations in culture, and to promote proliferation and leukemia-like disease in transplanted mice. We conclude that mutations in Janus kinases represent secondary drivers of leukemogenesis that cooperate with Spi1/Spib deletion. This mouse model represents a useful tool to study clonal evolution in B-ALL.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30355579      PMCID: PMC6234372          DOI: 10.1182/bloodadvances.2018019950

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  52 in total

1.  Precursor B cells of mouse bone marrow express two different complexes with the surrogate light chain on the surface.

Authors:  T H Winkler; A Rolink; F Melchers; H Karasuyama
Journal:  Eur J Immunol       Date:  1995-02       Impact factor: 5.532

2.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

Review 3.  Genetic Basis of Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

4.  PU.1 opposes IL-7-dependent proliferation of developing B cells with involvement of the direct target gene bruton tyrosine kinase.

Authors:  Darah A Christie; Li S Xu; Shereen A Turkistany; Lauren A Solomon; Stephen K H Li; Edmund Yim; Ian Welch; Gillian I Bell; David A Hess; Rodney P DeKoter
Journal:  J Immunol       Date:  2014-12-10       Impact factor: 5.422

Review 5.  Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.

Authors:  Maike Buchner; Srividya Swaminathan; Zhengshan Chen; Markus Müschen
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

Review 6.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

7.  Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.

Authors:  Tekla Hornakova; Judith Staerk; Yohan Royer; Elisabetta Flex; Marco Tartaglia; Stefan N Constantinescu; Laurent Knoops; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

8.  Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Authors:  Elisabeth Losdyck; Tekla Hornakova; Lorraine Springuel; Sandrine Degryse; Olga Gielen; Jan Cools; Stefan N Constantinescu; Elisabetta Flex; Marco Tartaglia; Jean-Christophe Renauld; Laurent Knoops
Journal:  J Biol Chem       Date:  2015-10-07       Impact factor: 5.157

9.  The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Authors:  Rajani K Vangala; Marion S Heiss-Neumann; Janki S Rangatia; Sheo M Singh; Claudia Schoch; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

10.  Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.

Authors:  Xiaotu Ma; Yu Liu; Yanling Liu; Ludmil B Alexandrov; Michael N Edmonson; Charles Gawad; Xin Zhou; Yongjin Li; Michael C Rusch; John Easton; Robert Huether; Veronica Gonzalez-Pena; Mark R Wilkinson; Leandro C Hermida; Sean Davis; Edgar Sioson; Stanley Pounds; Xueyuan Cao; Rhonda E Ries; Zhaoming Wang; Xiang Chen; Li Dong; Sharon J Diskin; Malcolm A Smith; Jaime M Guidry Auvil; Paul S Meltzer; Ching C Lau; Elizabeth J Perlman; John M Maris; Soheil Meshinchi; Stephen P Hunger; Daniela S Gerhard; Jinghui Zhang
Journal:  Nature       Date:  2018-02-28       Impact factor: 49.962

View more
  5 in total

1.  Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.

Authors:  Michelle Lim; Carolina R Batista; Bruno R de Oliveira; Rachel Creighton; Jacob Ferguson; Kurt Clemmer; Devon Knight; James Iansavitchous; Danish Mahmood; Mariano Avino; Rodney P DeKoter
Journal:  Mol Cell Biol       Date:  2020-08-28       Impact factor: 4.272

2.  IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity.

Authors:  Dennis Das Gupta; Christoph Paul; Nadine Samel; Maria Bieringer; Daniel Staudenraus; Federico Marini; Hartmann Raifer; Lisa Menke; Lea Hansal; Bärbel Camara; Edith Roth; Patrick Daum; Michael Wanzel; Marco Mernberger; Andrea Nist; Uta-Maria Bauer; Frederik Helmprobst; Malte Buchholz; Katrin Roth; Lorenz Bastian; Alina M Hartmann; Claudia Baldus; Koichi Ikuta; Andreas Neubauer; Andreas Burchert; Hans-Martin Jäck; Matthias Klein; Tobias Bopp; Thorsten Stiewe; Axel Pagenstecher; Michael Lohoff
Journal:  Cell Death Differ       Date:  2022-04-22       Impact factor: 15.828

3.  In vivo impact of JAK3 A573V mutation revealed using zebrafish.

Authors:  Faiza Basheer; Vilasha Bulleeraz; Viet Q T Ngo; Clifford Liongue; Alister C Ward
Journal:  Cell Mol Life Sci       Date:  2022-05-27       Impact factor: 9.207

4.  Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History.

Authors:  Livius Penter; Satyen H Gohil; Caleb Lareau; Leif S Ludwig; Erin M Parry; Teddy Huang; Shuqiang Li; Wandi Zhang; Dimitri Livitz; Ignaty Leshchiner; Laxmi Parida; Gad Getz; Laura Z Rassenti; Thomas J Kipps; Jennifer R Brown; Matthew S Davids; Donna S Neuberg; Kenneth J Livak; Vijay G Sankaran; Catherine J Wu
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

5.  Mutations in JAK/STAT and NOTCH1 Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders.

Authors:  Alexandra Butzmann; Kaushik Sridhar; Diwash Jangam; Hanbing Song; Amol Singh; Jyoti Kumar; Karen M Chisholm; Benjamin Pinsky; Franklin Huang; Robert S Ohgami
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.